

KYORIN, Eisai to develop & market drug for overactive bladder treatment in 4 ASEAN countries

31 March 2021 | News

Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN

Japanese firms KYORIN Pharmaceutical, a subsidiary of KYORIN Holdings, Inc., and Eisai Co., Ltd. have entered into a license agreement for development and distribution of vibegron, a therapeutic agent for overactive bladder, in four ASEAN (Association of Southeast Asian Nations) member states; Thailand, the Philippines, Malaysia and Brunei.

Based on this agreement, Eisai will acquire exclusive development and marketing rights from KYORIN for the agent in the said four countries, and will be responsible for submitting a New Drug Application for the agent.

Overactive bladder (OAB) is the name for a group of urinary symptoms characterized by urinary urgency, usually accompanied by increased daytime frequent urination and/or nocturia, and in some cases by urge urinary incontinence.

This agent is a novel β_3 -adrenergic receptor agonist administered once daily, acting selectively on β_3 receptors in the bladder, relaxing the bladder to enhance urine collection, and consequently improving the symptoms of urgency, urinary frequency and urge urinary incontinence associated with OAB.